According to the results of a study conducted in both the United States and Europe, adalimumab (Humira), a commonly used rheumatoid arthritis drug, also may help to reduce the symptoms of ankylosing spondylitis (AS). The findings were presented at the annual scientific meeting of the American College of Rheumatology in San Diego, Calif.
The study included 315 AS patients who had no success with at least 1 other form of therapy. The patients were randomly assigned either 40 mg of adalimumab or a placebo for 24 weeks. Researchers used 5 assessment methods to measure the patients' clinical responses to the treatment. The goal was a 20% improvement in AS signs and symptoms.
The researchers found that, at 12 and 24 weeks, more than twice as many patients taking the adalimumab reached the 20% symptom-improvement goal, compared with those taking the placebo. Some patients showed improvement as early as 2 weeks into the study.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs